BioNTech (BNTX) Is Up 27.3% After Novel Pumitamig Combo Data in Lung Cancer – Has The Bull Case Changed?

• BioNTech SE recently presented new clinical data from its diversified lung cancer program at the 2026 IASLC World Conference on Lung Cancer in Seoul, highlighting assets such as pumitamig, gotistobart and its mRNA-based immunotherapy candidates across multiple advanced NSCLC and SCLC settings.
• The first-in-class combination data pairing pumitamig, a PD-(L)1 x VEGF bispecific antibody, with the B7H3-targeted antibody-drug conjugate elfetabart drozuntecan underscores BioNTech’s push into complex “novel-novel” immunotherapy regimens that could broaden its oncology footprint beyond vaccines.
• We’ll now examine how BioNTech’s first-in-class pumitamig plus elfetabart drozuntecan lung cancer data may reshape its oncology-focused investment narrative.

Uncover the next big thing with 22 elite penny stocks that balance risk and reward.

BioNTech Investment Narrative Recap

To own BioNTech today, you need to believe its pivot from COVID-19 vaccines toward a multi-product oncology business can offset current losses and slower revenue growth, despite high R&D spend and CEO transition. The new lung cancer data around pumitamig and gotistobart speaks directly to that oncology story, but does not yet change the fact that late stage oncology readouts and eventual commercialization remain the key near term catalyst and the main execution risk.

Among recent developments, the updated overall survival signal from the PRESERVE-003 Phase 3 trial of gotistobart in squamous NSCLC ties in closely with the new WCLC lung data. Together with the pumitamig combinations, it reinforces that BioNTech’s most important potential catalysts sit in its lung cancer pipeline, where five pivotal Phase 3 studies and several novel novel regimens could be central to whether the current valuation, including the consensus price target of about US$121, proves reasonable.

Yet, against this progress in lung cancer, investors still need to weigh the risk that heavy R&D spending and ongoing losses could persist if late stage oncology trials...

Read the full narrative on BioNTech (it's free!)

BioNTech's narrative projects €2.2 billion revenue and €374.5 million earnings by 2029.

Uncover how BioNTech's forecasts yield a $120.62 fair value, a 3% upside to its current price.

Exploring Other Perspectives

Some of the most optimistic analysts, who were penciling in revenue of about €3.2 billion and earnings of roughly €607.1 million by 2029, see BioNTech’s oncology data cycle and novel lung combinations as evidence of much bigger long term potential than the baseline view, so if you are weighing these WCLC updates you should know how far those projections and assumptions can differ.

Explore 6 other fair value estimates on BioNTech - why the stock might be worth over 4x more than the current price!

Reach Your Own Conclusion

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• Our free BioNTech research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate BioNTech's overall financial health at a glance.

No Opportunity In BioNTech?

Our daily scans reveal stocks with breakout potential. Don't miss this chance:

• Outshine the giants: these 18 early-stage AI stocks could fund your retirement.
• Explore 24 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.
• AI is about to change healthcare. These 41 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com